The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Endogenous c-MYC (MYC) has been reported to be a potential pharmacological target to trigger ubiquitous tumor regression of pancreatic neuroendocrine tumors (PanNETs) and lung tumors. Recently inhibitors of bromodomain and extra-terminal (BET) family proteins have shown antitumor effects through the...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cell Death Dis
Auteurs principaux: Wong, C, Laddha, S V, Tang, L, Vosburgh, E, Levine, A J, Normant, E, Sandy, P, Harris, C R, Chan, C S, Xu, E Y
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2014
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237236/
https://ncbi.nlm.nih.gov/pubmed/25299775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2014.396
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires